Eagle Capital Management (New York)’s Constellation Pharmaceuticals, Inc. CNST Stock Holding History

Eagle Capital Management (New York)’s Portfolio CNST Stock Details CNST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-8,639	Closed	-$202K	–	66
2021 Q1	$202K	Hold	8,639	–	–	﹤0.01%	52
2020 Q4	$249K	Buy	+8,639	New	+$217K	﹤0.01%	52
2020 Q3	–	Sell	-8,639	Closed	-$260K	–	57
2020 Q2	$260K	Hold	8,639	–	–	﹤0.01%	54
2020 Q1	$272K	Hold	8,639	–	–	﹤0.01%	73
2019 Q4	$407K	Buy	+8,639	New	+$249K	﹤0.01%	54

Other funds holding CNST

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return

Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return

OPU

Omni Partners US Irvine, California $1.95B AUM

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return

PIM

Ponoi II Management San Francisco, California $38.3M AUM 32.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Eagle Capital Management (New York)'s CNST Position: Q2 2021 in Review

Eagle Capital Management (New York) sold out of Constellation Pharmaceuticals, Inc. (CNST) in Q2 2021, closing a stake of 8,639 shares — an estimated $202K sold.

Eagle Capital Management (New York) first reported a position in CNST in Q4 2019 and held it in 5 quarters. The position peaked at $407K in Q4 2019. 153 funds tracked by Wall St. Rank hold CNST as of Q2 2021.

Eagle Capital Management (New York) reported no remaining Constellation Pharmaceuticals, Inc. position as of Q2 2021 after selling out during the quarter.
Eagle Capital Management (New York) sold 8,639 Constellation Pharmaceuticals, Inc. shares in Q2 2021, an estimated $202K.
Eagle Capital Management (New York) first reported a position in Constellation Pharmaceuticals, Inc. in Q4 2019 and held it in 5 quarters.
Eagle Capital Management (New York)'s Constellation Pharmaceuticals, Inc. position peaked at $407K in Q4 2019.
153 funds tracked by Wall St. Rank held Constellation Pharmaceuticals, Inc. as of Q2 2021.

Based on Eagle Capital Management (New York)'s 13F filing for Q2 2021, filed 16 Aug 2021.